0001193125-23-128896.txt : 20230501 0001193125-23-128896.hdr.sgml : 20230501 20230501084202 ACCESSION NUMBER: 0001193125-23-128896 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230501 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20230501 DATE AS OF CHANGE: 20230501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acrivon Therapeutics, Inc. CENTRAL INDEX KEY: 0001781174 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 825125532 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41551 FILM NUMBER: 23870365 BUSINESS ADDRESS: STREET 1: 480 ARSENAL WAY, SUITE 100 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-207-8979 MAIL ADDRESS: STREET 1: 480 ARSENAL WAY, SUITE 100 CITY: WATERTOWN STATE: MA ZIP: 02472 8-K 1 d505148d8k.htm 8-K 8-K
false 0001781174 0001781174 2023-05-01 2023-05-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 1, 2023

 

 

Acrivon Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-41551   82-5125532

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

480 Arsenal Way, Suite 100

Watertown, Massachusetts

   02472
(Address of Principal Executive Offices)   (Zip Code)

(617) 207-8979

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value   ACRV   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02 Results of Operations and Financial Condition

In connection with its investor event taking place virtually on May 1, 2023, Acrivon Therapeutics, Inc. (the “Company”) will be updating its corporate presentation to include disclosure that the Company had $159.5 million of cash and marketable securities as of March 31, 2023 and to confirm its cash runway into at least the fourth quarter of 2024.

Because the Company’s financial results for the three months ended March 31, 2023 have not been finalized or audited, the preliminary statement of the Company’s cash and marketable securities as of March 31, 2023 in this Item 2.02 is subject to change, and the Company’s actual cash and marketable securities as of March 31, 2023 may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.

The information furnished under Item 2.02 of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Acrivon Therapeutics, Inc.
Dated: May 1, 2023     By:  

/s/ Peter Blume-Jensen

    Name: Peter Blume-Jensen, M.D., Ph.D.
    Title:   Chief Executive Officer and President
 EX-101.SCH 2 acrv-20230501.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 acrv-20230501_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 acrv-20230501_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 01, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001781174
Document Type 8-K
Document Period End Date May 01, 2023
Entity Registrant Name Acrivon Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-41551
Entity Tax Identification Number 82-5125532
Entity Address, Address Line One 480 Arsenal Way
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code (617)
Local Phone Number 207-8979
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol ACRV
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 6 d505148d8k_htm.xml IDEA: XBRL DOCUMENT 0001781174 2023-05-01 2023-05-01 false 0001781174 8-K 2023-05-01 Acrivon Therapeutics, Inc. DE 001-41551 82-5125532 480 Arsenal Way Suite 100 Watertown MA 02472 (617) 207-8979 false false false false Common Stock, $0.001 par value ACRV NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d505148d8k.htm acrv-20230501.xsd acrv-20230501_lab.xml acrv-20230501_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d505148d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "d505148d8k.htm" ] }, "labelLink": { "local": [ "acrv-20230501_lab.xml" ] }, "presentationLink": { "local": [ "acrv-20230501_pre.xml" ] }, "schema": { "local": [ "acrv-20230501.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "acrv", "nsuri": "http://acrivon.com/20230501", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d505148d8k.htm", "contextRef": "duration_2023-05-01_to_2023-05-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d505148d8k.htm", "contextRef": "duration_2023-05-01_to_2023-05-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acrivon.com//20230501/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001193125-23-128896-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-128896-xbrl.zip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